Name: Retatrutide & Cagrilintide Blend
Alias: RC10, CagriReta Research Peptide
CAS Registry number: Mixed peptides (No single CAS)
Sequence: N/A (Two lipidated long-acting peptides compound)
Molecular Formula: Mixed formula
Molecular Weight: Mixed molecular weight
Purity: ≥99% (Tested by HPLC)
Appearance: White lyophilized powder
Packing: 10mg*10vials (5mg Retatrutide + 5mg Cagrilintide per vial)
Product Group: Four-pathway multi-target metabolic composite peptide
Storage Conditions: Store at -20℃ in dry and dark environment, avoid repeated freeze-thaw cycles.
Brief Introduction:
RC10 is a fixed equal-proportion compound peptide exclusively for laboratory research, composed of triple receptor agonist Retatrutide and dual amylin/calcitonin agonist Cagrilintide.
Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors: suppresses appetite, boosts glucose-dependent insulin secretion, delays gastric emptying, and elevates systemic energy expenditure to accelerate lipolysis
PMC.
Cagrilintide dual activates amylin and calcitonin receptors to strengthen central satiety signals, further reduce food intake and stabilize postprandial blood glucose.
The two peptides act on complementary metabolic pathways, covering four core metabolic signal axes. They produce powerful synergistic effects on weight loss, visceral fat reduction, insulin resistance improvement and lipid homeostasis, widely used in severe obesity, type 2 diabetes, multi-hormone endocrine interaction and compound peptide pharmacology research.
Main Research Applications:
Multi-target glycemic regulation research: Used in cell and animal models to study four-pathway joint blood glucose stabilization and insulin sensitivity elevation mechanisms.
Severe obesity intervention research: Suitable for exploring synergistic appetite inhibition, visceral fat decomposition and long-term weight maintenance effects.
Energy balance research: Applied to investigate combined regulation of calorie intake and energy consumption.
Hepatic lipid metabolism research: For comparative analysis of non-alcoholic fatty liver relief and liver fat reduction.
Multi-receptor synergistic pharmacology research: Study interaction between triple incretin pathway and amylin receptor signaling.
Note:
This product is for laboratory research use only. It is not allowed for human/animal treatment, clinical trials or in vivo administration without ethical approval and official regulatory authorization.
